Valneva SE (EPA:VLA)
2.358
-0.037 (-1.54%)
Apr 24, 2026, 3:23 PM CET
Valneva SE Employees
Valneva SE had 674 employees as of December 31, 2025. The number of employees decreased by 39 or -5.47% compared to the previous year.
Employees
674
Change
-39
Growth
-5.47%
Revenue / Employee
€259,138
Profits / Employee
€170,908
Market Cap
416.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 674 | -39 | -5.47% |
| Jun 30, 2025 | 700 | - | - |
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | 762 | 262 | 52.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Genfit | 188 |
| Innate Pharma | 174 |
| MedinCell | 145 |
| Transgene | 145 |
| DBV Technologies | 117 |
| Nanobiotix | 103 |
| Inventiva | 77 |
Valneva SE News
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewsWire
- 7 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 21 days ago - Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewsWire
- 4 weeks ago - Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC - GlobeNewsWire
- 4 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewsWire
- 4 weeks ago - Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges - GuruFocus
- 4 weeks ago - An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive - WSJ
- 4 weeks ago - Lyme disease vaccine 70 percent effective: Pfizer - The Hill